Fischer G W, Wilson S R, Hunter K W
J Clin Immunol. 1982 Apr;2(2 Suppl):31S-35S. doi: 10.1007/BF00918364.
Group B streptococci (GBS) remains a major cause of morbidity and mortality in newborn babies, despite antibiotic therapy, Recent studies suggest that phagocytosis and killing of GBS is ineffective due to a deficiency in anti-GBS antibody. Using an opsonophagocytic bacterial assay and a suckling rat model of GBS sepsis, we analyzed a modified human immunoglobulin for opsonic and protective antibody. Immune globulin (IGIV) prepared for intravenous use (Gamimune, Cutter Laboratories, Inc.) was highly protective in this experimental GBS model. Using the opsonophagocytic assay, antibody activity to several strains of types Ia, II, and III GBS were also demonstrated with IGIV. To ensure that the IGIV activity was in fact antibody, globulin from IGIV was isolated and analyzed. Purified IgG retained opsonic activity in vitro and also provided protection in experimental GBS disease. Variation in the quantity of IgG necessary for protection was observed in different GBS strains. Since IGIV has opsonic and protective activity against several strains and serotypes of GBS, its intravenous administration may provide a valuable adjunct to standard antibiotic therapy for neonatal GBS infections.
尽管有抗生素治疗，但B族链球菌（GBS）仍然是新生儿发病和死亡的主要原因。最近的研究表明，由于抗GBS抗体缺乏，对GBS的吞噬和杀灭作用无效。我们使用调理吞噬细菌试验和GBS败血症乳鼠模型，分析了一种改良的人免疫球蛋白的调理和保护抗体作用。静脉用免疫球蛋白（IGIV，商品名Gamimune，卡特实验室公司生产）在该实验性GBS模型中具有高度保护作用。使用调理吞噬试验，还证明了IGIV对Ia、II和III型GBS的几种菌株具有抗体活性。为确保IGIV的活性实际上是抗体，对IGIV中的球蛋白进行了分离和分析。纯化的IgG在体外保留了调理活性，并且在实验性GBS疾病中也提供了保护作用。在不同的GBS菌株中观察到保护所需的IgG量存在差异。由于IGIV对几种GBS菌株和血清型具有调理和保护活性，其静脉给药可能为新生儿GBS感染的标准抗生素治疗提供有价值的辅助治疗。
